Extracellular Matrix Patches Market (2023 - 2030) Size, Share & Trends Analysis Report By Raw Material (Bovine, Porcine), By Application (Soft Tissue Repair, Vascular Repair & Reconstruction), By Region, And Segment Forecasts

Extracellular Matrix Patches Market Summary

As per the Centers for Disease Control and Prevention (CDC) 2022 report, 18.2 million individuals had coronary artery disease, and 70% of these patients received surgery. In addition, about 40,000 neonates are born with CHD in the U.S. each year.

Increasing adoption of extracellular matrix (ECM) in hernia and pelvic reconstruction surgeries promotes the growth of these products. For instance, abdominal wall hernia is amongst the commonest surgeries around the world. According to Medscape, in the U.S., more than 1 million abdominal wall hernia surgeries are conducted annually. Many companies are focusing on the development of extracellular matrix for pelvic reconstruction and hernia repair. In April 2021, Aroa Biosurgery, a soft tissue regeneration organization, launched Myriad Morcells, Myriad Matrix morcellized format. It received the U.S. FDA clearance on 6th April.

Recent technological advancements in extracellular matrix for soft tissue repair and wound healing procedures propel product demand. For instance, AltiPly, manufactured by Aziyo Biologics, is a ready-to-use patch that requires no rehydration and ensures ease in handling at room temperature. It is used in cases of venous leg ulcers, diabetic foot ulcers, and pressure wounds and involves proprietary processing that improves growth level factors and enhances the healing process.

The high cost of these ECM grafts may negatively impact market growth. However, reimbursement assistance from governments for their will continue to drive demand. For instance, eight Current Procedural Terminology (CPT) codes have been identified by the American Medical Association for various applications of OASIS Matrix products, manufactured by Smith & Nephew. The product can be reimbursed in three settings: out of hospital (HOPD), physician in-office (QHP), and ambulatory wound care center (ASC).

Rising awareness of the benefits of biological patches over synthetic ones is also one of the significant factors contributing to the growth of ECM patches. However, in the past few years, many of these products have undergone recalls, which in turn, hinder its adoption levels. In addition, the use of extracellular matrix grafts involves various complications such as allergies, chronic inflammation, pain, swelling, and redness, which may adversely impact its growth.

Application Insights

Based on applications the extracellular matrix (ECM) patches market of extracellular is segmented into soft tissue repair, cardiac repair, dural repair, pericardial repair, wound healing and vascular repair & reconstruction. Soft tissue repair dominated the segment with a revenue share of 28.0% in 2022. Increasing number of hernia repair surgeries–particularly inguinal hernia, rising prevalence of trauma surgeries, and high treatment rates are some of the important factors that propel the market. Inguinal hernia repair is one of the most common surgical procedures performed globally, with more than 20 million patients each year.  In addition, growing adoption and awareness of the extracellular matrix among healthcare providers, especially in developed countries, is expected to drive the application segment.

For instance, Medeor Matrix manufactured by Koninklijke DSM N.V. is used for various soft tissue applications such as pelvic floor reconstruction, plastic and reconstructive surgeries, and abdominal wall repair. It is manufactured using the OPTRIX process, which eliminates cells, inactivates viruses, disinfects tissues, and preserves ECM components.

Vascular repair and reconstruction is expected to expand at the fastest CAGR of 8.5% over the forecast period. The rising number of vascular surgeries, increasing prevalence of vascular diseases, and surging geriatric population are among the important factors anticipated to boost demand over the forecast period. According to Medical Travel Brand Management: Success Strategies for Global Healthcare, there were an estimated 13.2 million vascular surgeries performed worldwide in 2022.

In addition, many public and private organizations are supporting research studies in the area of extracellular matrix to treat vascular conditions, which may further propel the segment. For instance, the European Society for Vascular Surgery promotes high-quality research and advises regulatory bodies on matters concerning vascular diseases. It shares partnerships with various ECM patch manufacturers, including Medtronic, Boston Scientific Corporation, Cook Medical, and Smith & Nephew. In June 2021, Axio Biosolutions announced the FDA clearance for t Axiostat Patch, which is expected to assist in controlling moderate to severe bleeding during vascular procedures, puncture & surgical debridement sites and more;

Raw Material Insights

Based on raw material the market of extracellular matrix patches is segmented into porcine, bovine and others. Porcine dominated the segment with a revenue share of 40.0% in 2022, owing to the high usage of these grafts in repair and reconstructive surgeries, as it is similar to human collagen and reduces the possibility of allergic responses. These porcine-derived grafts offer several benefits such as durability, pliability, and minimal scar formation, which spurs their demand. Moreover, the wide availability of these grafts and high adoption levels drive segment growth.

ECM patches derived from bovine sources is expected to grow at the fastest CAGR of 8.2% over the forecast period. The rising number of bovine-based products, coupled with growing applications in soft tissue repair, vascular repair and reconstruction, dural repair, pericardial repair, and others, have led to an increase in demand for these products. Furthermore, these patches are preferred over other materials as they offer superior biocompatibility, reduced risk of infection, and ease in handling during surgical procedures. Additionally, high availability of cattle’s and lower price is also driving the growth of the segment 

ECM patches derived from other sources, such as human-derived dermis and equine derived pericardium, also held a significant market share in 2022. An increasing number of research studies by private companies, coupled with high investments in R&D, enable the adoption of other raw materials for the manufacturing of ECM patches. Moreover, many public and private organizations are supporting the development of ECM grafts through the donation of human dermis. For instance, MTF Biologics is a non-profit organization engaged in providing human allograft tissue. One of its products, AlloPatch HD Acellular Dermis, is a human allograft derived from donated human tissue.

Regional Insights

North America dominated the market with a revenue share of 48.0% in 2022. Increasing incidence of cardiovascular diseases and defects, sports injuries, and trauma cases are responsible for the growing demand in this region. According to the latest estimates by the American Association for the Surgery of Trauma, each year, about 150,000 deaths were reported due to injuries in the U.S. According to National Institute of Health (NIH) 50% of Americans between 45 and 84 years of age have atherosclerosis. Presence of a large number of market players further increases the availability of ECM patches in this region.

The presence of technologically advanced research labs, an increasing amount of research funds, and high healthcare expenditure are among the significant factors contributing toward the growth of this regional market. Higher adoption and awareness of advanced ECM patches among healthcare providers and patients further impels demand. Favorable reimbursement policies will also boost the market growth.

Asia Pacific is expected to grow at a fastest CAGR of 9.6% over the forecast period. High prevalence of cardiovascular diseases, increasing incidence of trauma, and rising number of surgeries may propel the market. According to estimates, about 200,000 infants are born in India each year with congenital cardiac disease, which has a birth frequency of 9/1000. One-fifth of them are most likely to have significant defects that must be treated during the first year of life. Rising healthcare expenditure and growing disease burden are likely to boost demand in the coming years. However, the high cost of the product may negatively impact the growth in this region.

Key Companies & Market Share Insights

Market players are undertaking strategies such as mergers and acquisitions, partnerships and agreements for the expanding their regional presence and marketing and distribution of their products. In September 2021, Terumo Corporation announced the launch of PANTHER, a global surgical graft study. This study is both retrospective and prospective and examines a wide variety of knitted and woven surgical grafts as well as cardiovascular patches.

In February 2020, CorMatrix Cardiovascular, Inc., announced that it received the FDA approval to enroll 20 additional patients and expand the adult arm for feasibility study of Cor TRICUSPID ECM valve for adult and pediatric patients. Some of the players in the global extracellular matrix patches market are:

• Cook Group

• Coloplast Group

• Smith & Nephew

• Koninklijke DSM N.V.

• MTF Biologics

• Boston Scientific Corporation

• Medtronic

• Baxter

• Aziyo Biologics

• Admedus Ltd.

Extracellular Matrix Patches Market Report Scope

Global Extracellular Matrix Patches Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For the purpose of this study, Grand View Research has segmented the global extracellular matrix patchesmarket report on the basis of application, raw material, and region:

• Application Outlook (Revenue, USD Million, 2018 - 2030)

  • Cardiac Repair

  • Vascular Repair & Reconstruction

  • Pericardial Repair

  • Dural Repair

  • Soft Tissue Repair

  • Wound Healing

• Raw Material Outlook (Revenue, USD Million, 2018 - 2030)

  • Bovine

  • Porcine

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Sweden

    • Norway

    • Denmark

  • Asia Pacific

    • China

    • Japan

    • India

    • Australia

    • Thailand

    • South Korea

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa

    • Saudi Arabia

    • South Africa

    • UAE

    • Kuwait